Biodexa Ev To Free Cash Flow vs Begin Period Cash Flow Analysis

BDRX Stock

4.35 0.19 4.57%

Biodexa Pharmaceticals financial indicator trend analysis is way more than just evaluating Biodexa Pharmaceticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biodexa Pharmaceticals is a good investment. Please check the relationship between Biodexa Pharmaceticals Ev To Free Cash Flow and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Ev To Free Cash Flow vs Begin Period Cash Flow

Ev To Free Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biodexa Pharmaceticals Ev To Free Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Biodexa Pharmaceticals' Ev To Free Cash Flow and Begin Period Cash Flow is 0.02. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Biodexa Pharmaceticals, assuming nothing else is changed. The correlation between historical values of Biodexa Pharmaceticals' Ev To Free Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Biodexa Pharmaceticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Ev To Free Cash Flow i.e., Biodexa Pharmaceticals' Ev To Free Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Biodexa Pharmaceticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.65 in 2025, whereas Selling General Administrative is likely to drop slightly above 3.9 M in 2025.

Biodexa Pharmaceticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Net Receivables	Short Term Debt	Common Stock	Inventory	Net Tangible Assets	Common Stock Shares Outstanding
Total Assets		0.35	0.67	0.99	0.84	-0.72	0.18	0.7	0.81	0.96	0.59	-0.32	0.81	0.66	0.66	-0.07	0.72	0.88	0.94	0.28	0.63	-0.29	-0.35	0.46	-0.34	-0.33
Other Current Liab	0.35		0.84	0.25	0.24	-0.06	0.23	0.15	0.02	0.48	-0.22	-0.34	0.02	0.35	0.12	-0.2	0.66	0.07	0.44	0.12	0.68	0.11	0.0	0.26	-0.06	0.06
Total Current Liabilities	0.67	0.84		0.55	0.6	-0.21	0.25	0.65	0.28	0.77	0.3	-0.33	0.28	0.65	0.47	-0.2	0.91	0.37	0.71	0.42	0.76	0.05	-0.17	0.42	-0.26	-0.12
Total Stockholder Equity	0.99	0.25	0.55		0.82	-0.79	0.12	0.63	0.86	0.91	0.56	-0.28	0.86	0.55	0.62	-0.01	0.6	0.92	0.9	0.18	0.58	-0.36	-0.33	0.4	-0.3	-0.31
Property Plant And Equipment Net	0.84	0.24	0.6	0.82		-0.38	0.22	0.79	0.53	0.87	0.69	-0.43	0.53	0.63	0.86	-0.14	0.66	0.63	0.79	0.53	0.56	-0.12	-0.54	0.62	-0.45	-0.54
Net Debt	-0.72	-0.06	-0.21	-0.79	-0.38		-0.03	-0.29	-0.97	-0.51	-0.23	0.05	-0.97	-0.14	-0.1	-0.08	-0.19	-0.93	-0.55	0.16	-0.24	0.39	0.11	-0.12	0.07	0.05
Retained Earnings	0.18	0.23	0.25	0.12	0.22	-0.03		0.14	0.06	0.21	0.13	-0.91	0.06	0.41	0.35	-0.96	0.35	0.06	0.2	0.5	-0.02	0.86	-0.69	0.73	-0.71	-0.67
Accounts Payable	0.7	0.15	0.65	0.63	0.79	-0.29	0.14		0.46	0.72	0.82	-0.13	0.46	0.7	0.69	-0.06	0.73	0.53	0.65	0.64	0.4	-0.06	-0.39	0.41	-0.38	-0.39
Cash	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46		0.61	0.43	-0.08	1.0	0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Assets Total	0.96	0.48	0.77	0.91	0.87	-0.51	0.21	0.72	0.61		0.58	-0.38	0.61	0.74	0.76	-0.13	0.83	0.71	0.98	0.33	0.69	-0.21	-0.35	0.5	-0.37	-0.34
Non Currrent Assets Other	0.59	-0.22	0.3	0.56	0.69	-0.23	0.13	0.82	0.43	0.58		-0.14	0.43	0.61	0.78	-0.07	0.48	0.48	0.57	0.59	0.14	-0.08	-0.39	0.27	-0.46	-0.4
Other Assets	-0.32	-0.34	-0.33	-0.28	-0.43	0.05	-0.91	-0.13	-0.08	-0.38	-0.14		-0.08	-0.42	-0.52	0.87	-0.38	-0.12	-0.35	-0.47	-0.19	-0.7	0.73	-0.8	0.71	0.73
Cash And Short Term Investments	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46	1.0	0.61	0.43	-0.08		0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Liabilities Total	0.66	0.35	0.65	0.55	0.63	-0.14	0.41	0.7	0.31	0.74	0.61	-0.42	0.31		0.68	-0.36	0.89	0.38	0.74	0.7	0.44	0.14	-0.48	0.55	-0.48	-0.48
Other Current Assets	0.66	0.12	0.47	0.62	0.86	-0.1	0.35	0.69	0.26	0.76	0.78	-0.52	0.26	0.68		-0.3	0.61	0.36	0.74	0.54	0.3	0.07	-0.59	0.55	-0.57	-0.58
Other Stockholder Equity	-0.07	-0.2	-0.2	-0.01	-0.14	-0.08	-0.96	-0.06	0.05	-0.13	-0.07	0.87	0.05	-0.36	-0.3		-0.31	0.05	-0.12	-0.46	0.08	-0.87	0.63	-0.65	0.76	0.62
Total Liab	0.72	0.66	0.91	0.6	0.66	-0.19	0.35	0.73	0.32	0.83	0.48	-0.38	0.32	0.89	0.61	-0.31		0.41	0.79	0.6	0.67	0.09	-0.31	0.52	-0.4	-0.28
Total Current Assets	0.88	0.07	0.37	0.92	0.63	-0.93	0.06	0.53	0.99	0.71	0.48	-0.12	0.99	0.38	0.36	0.05	0.41		0.71	0.11	0.44	-0.4	-0.23	0.27	-0.21	-0.18
Intangible Assets	0.94	0.44	0.71	0.9	0.79	-0.55	0.2	0.65	0.63	0.98	0.57	-0.35	0.63	0.74	0.74	-0.12	0.79	0.71		0.24	0.57	-0.25	-0.3	0.42	-0.34	-0.29
Short Long Term Debt Total	0.28	0.12	0.42	0.18	0.53	0.16	0.5	0.64	0.05	0.33	0.59	-0.47	0.05	0.7	0.54	-0.46	0.6	0.11	0.24		0.31	0.46	-0.55	0.64	-0.55	-0.56
Net Receivables	0.63	0.68	0.76	0.58	0.56	-0.24	-0.02	0.4	0.34	0.69	0.14	-0.19	0.34	0.44	0.3	0.08	0.67	0.44	0.57	0.31		-0.24	0.03	0.39	-0.03	0.03
Short Term Debt	-0.29	0.11	0.05	-0.36	-0.12	0.39	0.86	-0.06	-0.38	-0.21	-0.08	-0.7	-0.38	0.14	0.07	-0.87	0.09	-0.4	-0.25	0.46	-0.24		-0.51	0.53	-0.52	-0.5
Common Stock	-0.35	0.0	-0.17	-0.33	-0.54	0.11	-0.69	-0.39	-0.19	-0.35	-0.39	0.73	-0.19	-0.48	-0.59	0.63	-0.31	-0.23	-0.3	-0.55	0.03	-0.51		-0.57	0.81	0.94
Inventory	0.46	0.26	0.42	0.4	0.62	-0.12	0.73	0.41	0.22	0.5	0.27	-0.8	0.22	0.55	0.55	-0.65	0.52	0.27	0.42	0.64	0.39	0.53	-0.57		-0.44	-0.63
Net Tangible Assets	-0.34	-0.06	-0.26	-0.3	-0.45	0.07	-0.71	-0.38	-0.17	-0.37	-0.46	0.71	-0.17	-0.48	-0.57	0.76	-0.4	-0.21	-0.34	-0.55	-0.03	-0.52	0.81	-0.44		0.78
Common Stock Shares Outstanding	-0.33	0.06	-0.12	-0.31	-0.54	0.05	-0.67	-0.39	-0.14	-0.34	-0.4	0.73	-0.14	-0.48	-0.58	0.62	-0.28	-0.18	-0.29	-0.56	0.03	-0.5	0.94	-0.63	0.78

Click cells to compare fundamentals

Biodexa Pharmaceticals Account Relationship Matchups

Biodexa Pharmaceticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Other Current Liab	2.4M	1.2M	1.3M	5.0M	4.5M	2.5M
Total Current Liabilities	3.0M	1.8M	1.9M	5.6M	5.0M	3.8M
Total Stockholder Equity	6.7M	10.5M	3.2M	4.7M	4.2M	4.0M
Property Plant And Equipment Net	542K	1.2M	831K	571K	513.9K	488.2K
Net Debt	(7.3M)	(9.3M)	(2.2M)	(5.5M)	(6.3M)	(6.6M)
Retained Earnings	(122.4M)	(127.8M)	(135.3M)	(144.8M)	(130.3M)	(123.8M)
Accounts Payable	337K	485K	339K	314K	282.6K	268.5K
Cash	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Assets Total	542K	1.2M	837K	3.5M	3.2M	3.0M
Non Currrent Assets Other	2.6M	(542K)	(1.2M)	(837K)	(753.3K)	(715.6K)
Cash And Short Term Investments	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Liabilities Total	110K	619.5K	463K	295K	265.5K	252.2K
Other Current Assets	258K	607K	376K	355K	319.5K	303.5K
Other Stockholder Equity	74.4M	85.2M	83.7M	86.7M	99.7M	59.2M
Total Liab	3.1M	2.5M	2.4M	5.9M	5.3M	5.8M
Total Current Assets	9.3M	11.8M	4.7M	7.0M	6.3M	10.0M
Intangible Assets	10.1M	10.1M	6K	2.9M	2.6M	2.5M
Short Long Term Debt Total	260K	766K	624K	464K	417.6K	396.7K
Net Receivables	95K	33K	329K	704K	633.6K	455.7K
Liabilities And Stockholders Equity	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Accumulated Other Comprehensive Income	53.7M	53.5M	53.0M	61.5M	70.8M	53.6M
Short Term Debt	200K	146K	161K	169K	152.1K	144.5K
Common Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Common Stock Shares Outstanding	5.4K	10.1K	12.4K	31.6K	36.3K	38.1K
Capital Lease Obligations	153K	766K	624K	464K	417.6K	504.3K
Net Invested Capital	6.8M	10.5M	3.2M	4.7M	4.2M	7.9M
Property Plant And Equipment Gross	2.1M	2.8M	2.5M	2.3M	2.1M	2.8M
Capital Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Net Working Capital	6.3M	9.9M	2.8M	1.5M	1.3M	1.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biodexa Ev To Free Cash Flow vs Begin Period Cash Flow Analysis

Ev To Free Cash Flow vs Begin Period Cash Flow

Ev To Free Cash Flow vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Begin Period Cash Flow

Biodexa Pharmaceticals fundamental ratios Correlations

Biodexa Pharmaceticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodexa Pharmaceticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Intangible Assets	+ 0.98	Non Current Assets Total
Non Current Assets Total	+ 0.96	Total Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.93	Net Debt
Other Assets	- 0.91	Retained Earnings
Short Term Debt	- 0.87	Other Stockholder Equity